<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1910200225
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        INLYTA 1 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AXITINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3258.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Inlyta is a medicine containing the active substance axitinib. Axitinib reduces the blood supply to the tumour and slows down the growth of cancer.</p><p>&nbsp;</p><p>Inlyta is indicated for the treatment of advanced kidney cancer (advanced renal cell carcinoma) in adults, when another medicine (called sunitinib or a cytokine) is no longer stopping disease from progressing.</p><p>&nbsp;</p><p>If you have any questions about how this medicine works or why this medicine has been prescribed for you, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Inlyta:</strong></p><p>If you are allergic to axitinib or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>If you think you may be allergic, ask your doctor for advice.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p><strong>Talk to your doctor or nurse before taking Inlyta:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have high blood pressure.</strong><br />Inlyta can raise your blood pressure. It is important to check your blood pressure before you take this medicine, and regularly while you are taking it. If you have high blood pressure (hypertension) you may be treated with medicines to reduce the blood pressure. Your doctor should make sure that your blood pressure is under control before starting Inlyta treatment, and while on treatment with this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have thyroid gland problems.</strong><br />Inlyta can cause thyroid gland problems. Tell your doctor if you get tired more easily, generally feel colder than other people, or your voice deepens whilst taking this medicine. Your thyroid function should be checked before you take Inlyta and regularly while you are taking it. If your thyroid gland is not producing enough thyroid hormone before, or while on treatment with this medicine, you should be treated with thyroid hormone replacement.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have had a recent problem with blood clots in your veins and arteries (types of blood vessels), including stroke, heart attack, embolism, or thrombosis. </strong></p><p>Get emergency help right away and call your doctor if you get symptoms such as chest pain or pressure; pain in your arms, back, neck or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; headache; vision changes; or dizziness while on treatment with this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you suffer from bleeding problems.</strong></p><p>Inlyta may increase your chance of bleeding. Tell your doctor if you have any bleeding, coughing up of blood or bloody sputum while on treatment with this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If during treatment with this medicine you get severe stomach (abdominal) pain or stomach pain that does not go away.</strong></p><p>Inlyta may increase the risk of developing a hole in the stomach or intestine or formation of fistula (abnormal tube-like passage from one normal body cavity to another body cavity or the skin).<br />Tell your doctor if you have severe abdominal pain while on treatment with this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are going to have an operation or if you have an unhealed wound.</strong><br />Your doctor should stop Inlyta at least 24 hours before your operation as it may affect wound healing. Your treatment with this medicine should be restarted when the wound has adequately healed.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If during treatment with this medicine, you get symptoms such as headache, confusion, seizures (fits), or changes in vision with or without high blood pressure.</strong></p><p>Get emergency help right away and call your doctor. This could be a rare neurological side effect named posterior reversible encephalopathy syndrome.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have liver problems.</strong></p><p>Your doctor should do blood tests to check your liver function before and during treatment with Inlyta.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If during treatment with this medicine, you get symptoms such</strong><strong> as</strong><strong> </strong><strong>excessive tiredness, swelling of the abdomen, legs or ankles, shortness of breath, or protruding neck veins.</strong></p><p>Inlyta may increase the risk of developing heart failure events. Your doctor should monitor for signs or symptoms of heart failure events periodically throughout treatment with axitinib.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>Inlyta is not recommended for people aged under 18. This medicine has not been studied in children and adolescents.</p><p>&nbsp;</p><p><strong>Other medicines and Inlyta</strong></p><p>Some medicines may affect Inlyta, or be affected by it. Please tell your doctor, pharmacist or nurse about all the medicines you have recently taken, are currently taking, or plan to take, including medicines obtained without a prescription, vitamins, and herbal medicines. The medicines listed in this leaflet may not be the only ones that could interact with Inlyta.</p><p>&nbsp;</p><p>The following medicines may increase the risk of side effects with Inlyta:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole or itraconazole, used to treat fungal infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clarithromycin, erythromycin or telithromycin, antibiotics used to treat bacterial infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atazanavir, indinavir, nelfinavir, ritonavir or saquinavir, used to treat HIV infections/AIDS;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nefazodone, used to treat depression.</p><p>&nbsp;</p><p>The following medicines may reduce the effectiveness of Inlyta:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, rifabutin or rifapentin, used to treat tuberculosis (TB);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dexamethasone, a steroid medicine prescribed for many different conditions, including serious illnesses;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin, carbamazepine or phenobarbital, anti-epileptics used to stop seizures or fits;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (<em>Hypericum perforatum</em>), a herbal product used to treat depression.</p><p>&nbsp;</p><p>You<em> </em><strong>should not </strong>take these medicines<em> </em>during your treatment with Inlyta. If you are taking any of them, tell your doctor, pharmacist or nurse. Your doctor may change the dose of these medicines, change the dose of Inlyta, or switch you to a different medicine.</p><p>&nbsp;</p><p>Inlyta may increase side effects associated with theophylline, used to treat asthma or other lung diseases.</p><p>&nbsp;</p><p><strong>Inlyta with food and drink</strong></p><p>&nbsp;</p><p>Do not take this medicine with grapefruit or grapefruit juice, as it may increase the chance of side effects.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inlyta could harm an unborn baby or breast-fed baby.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take this medicine during pregnancy. Talk to your doctor before taking it if you are pregnant or might become pregnant.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use a reliable method of contraception while you are taking Inlyta and up to 1 week after the last dose of this medicine, to prevent pregnancy.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not breast-feed during treatment with Inlyta. If you are breast-feeding, your doctor should discuss with you whether to discontinue breast-feeding or discontinue Inlyta treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>If you experience dizziness and/or feel tired while on treatment with Inlyta, take special care when driving or using machines.</p><p>&nbsp;</p><p><strong>Inlyta</strong> <strong>contains lactose </strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p><strong>Inlyta contains sodium</strong></p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol (23 mg) sodium per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor, pharmacist or nurse if you are not sure.</p><p>&nbsp;</p><p>The recommended dose is 5&nbsp;mg twice a day. Your doctor may subsequently increase or decrease your dose depending on how you tolerate treatment with Inlyta.</p><p>&nbsp;</p><p>Swallow the tablets whole with water, with or without food. Take the Inlyta doses approximately 12&nbsp;hours apart.</p><p>&nbsp;</p><p><strong>If you take more Inlyta than you should</strong></p><p>If you accidentally take too many tablets or a higher dose than you need, contact a doctor for advice right away. If possible, show the doctor the pack, or this leaflet. You may require medical attention.</p><p>&nbsp;</p><p><strong>If you forget to take Inlyta</strong></p><p>Take your next dose at your regular time. Do not take a double dose to make up for the forgotten tablets.</p><p>&nbsp;</p><p><strong>If you vomit while taking Inlyta</strong></p><p>If you vomit, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.</p><p>&nbsp;</p><p><strong>If you stop taking Inlyta</strong></p><p>If you are not able to take this medicine as your doctor prescribed or you feel you do not need it anymore, contact your doctor right away.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Some side effects could be serious. You must immediately contact your doctor if you experience any of those following serious side effects (see also section&nbsp;2 &ldquo;What you need to know before you take Inlyta&rdquo;):</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart failure events. </strong>Tell your doctor if you experience excessive tiredness, swelling of the abdomen, legs, or ankles, shortness of breath, or protruding neck veins.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood clots in your veins and arteries (types of blood vessels), including stroke, heart attack, embolism, or thrombosis.</strong> Get emergency help right away and call your doctor if you get symptoms such as chest pain or pressure; pain in your arms, back, neck or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; headache; vision changes: or dizziness.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bleeding. </strong>Tell your doctor right away if you have any of these symptoms or a serious bleeding problem during treatment with Inlyta: black tarry stools, coughing up of blood or bloody sputum, or change in your mental status.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hole in the stomach or intestine or formation of fistula (abnormal tube-like passage from one normal body cavity to another body cavity or the skin).</strong> Tell your doctor if you have severe abdominal pain.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Severe increase in blood pressure (hypertensive crisis).</strong> Tell your doctor if you have a very high blood pressure, severe headache, or severe chest pain.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Reversible swelling of the brain (posterior reversible encephalopathy syndrome).</strong> Get emergency help right away and call your doctor if you get symptoms such as headache, confusion, seizures (fits), or changes in vision with or without high blood pressure.</p><p>&nbsp;</p><p>Other side effects with Inlyta may include:</p><p>&nbsp;</p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure, or increases in blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, feeling or being sick (nausea or vomiting), stomach ache, indigestion, soreness of the mouth, tongue or throat, constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, cough, hoarseness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of energy, feeling weak or tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Under-active thyroid gland (may show in your blood tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness and swelling of the palms of the hands or soles of the feet (hand-foot syndrome), skin rash, dryness of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain, pain in hands or feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protein in the urine (may show in your urine tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, taste disturbance or loss of taste</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration (loss of body fluids)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flatulence (wind), haemorrhoids, bleeding from gums, bleeding from the rectum, a burning or stinging sensation in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyper-active thyroid gland (may show in your blood tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat or nose and throat irritation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nose bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin itching, redness of the skin, hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringing/sound in the ears (tinnitus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in the number of red blood cells (may show in your blood tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in the number of blood platelets (cells that help blood to clot) (may show in your blood tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Presence of red blood cells in the urine (may show in your urine tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the levels of different chemicals/enzymes in the blood (may show in your blood tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in the number of red blood cells (may show in your blood tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the abdomen, legs, or ankles, protruding neck veins, excessive tiredness, shortness of breath (signs of heart failure events)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fistula (abnormal tube like passage from one normal body cavity to another body cavity or the skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the gall bladder</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in the number of white blood cells (may show in your blood tests)</p><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. &nbsp;By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Saudi Arabia</p><p>National Pharmacovigilance &nbsp;Centre ( NPC )</p><ul><li>Call center : 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the blister foil or bottle after &ldquo;EXP&rdquo;. The expiry date refers to the last day of the month.</p><p>&nbsp;</p><p>This medicine should be stored below 30<strong>&deg;</strong>C.</p><p>&nbsp;</p><p>Do not use any pack that is damaged or shows signs of tampering.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp; The active substance is axitinib. Inlyta film-coated tablets come in different strengths.</p><p>Inlyta 1&nbsp;mg: each tablet contains 1&nbsp;mg axitinib</p><p>Inlyta 5&nbsp;mg: each tablet contains 5&nbsp;mg axitinib</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, hypromellose 2910 (15 mPa&middot;s), titanium dioxide (E171), triacetin (E1518), iron oxide red (E172) (see section 2 Inlyta contains lactose (milk sugar)).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Inlyta 1 mg film-coated tablets are red, oval and debossed with “Pfizer” on one side and “1 XNB” on the other. Inlyta 1 mg is available in blisters of 14 tablets. Each blister pack contains 28 tablets or 56 tablets.
	
	For the pack of 56 tablets, the pack contains 4 blisters each blister has 14 film coated tablets (4 X 14).
	
	
	Inlyta 5 mg film-coated tablets are red, triangular and debossed with “Pfizer” on one side and “5 XNB” on the other. Inlyta 5 mg is available in blisters of 14 tablets. Each blister pack contains 28 tablets or 56 tablets.
	
	For the pack of 56 tablets, the pack contains 4 blisters each blister has 14 film coated tablets (4 X 14).
	
	Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Marketing Authorisation Holder</strong></p><p>&nbsp;</p><p>Pfizer Limited</p><p>Ramsgate Road</p><p>Sandwich, Kent CT13&nbsp;9NJ</p><p>United Kingdom</p><p>&nbsp;</p><p><strong>Manufacturer </strong></p><p>&nbsp;</p><p>Pfizer Manufacturing Deutschland GmbH</p><p>Betriebsst&auml;tte Freiburg</p><p>Mooswaldallee 1</p><p>79090 Freiburg</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إنليتا هو دواء يحتوي على المادة الفعالة أكسيتينيب. يعمل أكسيتينيب على تقليل وصول الدم إلى الورم ويبطئ من نمو السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم إنليتا في حالات البالغين لعلاج سرطان الكلى المتقدم (سرطان الخلايا الكلوية المتقدم)، عندما لا يعود بإمكان الأدوية الأخرى (تُدعى سونيتينيب أو سيتوكين) إيقاف المرض من التقدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة حول كيفية عمل هذا الدواء أو سبب وصفه لك، فاسأل طبيبك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>- موانع استعمال إنليتا</strong></p><p dir="RTL">إذا كنت مصابًا بالحساسية تجاه أكسيتينيب أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">إذا كنت تعتقد بأنك مصاب بالحساسية، فاطلب المشورة من طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب - الاحتياطات عند استعمال </strong><strong>إنليتا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استشر الطبيب أو الممرضة قبل تناول إنليتا:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من ارتفاع ضغط الدم.</strong><br />يمكن لإنليتا أن يرفع ضغط دمك. من المهم أن تقوم بفحص ضغط دمك قبل تناول هذا الدواء، وفحصه بشكل منتظم أثناء تناوله. إذا كنت تعاني من ضغط الدم المرتفع (ارتفاع ضغط الدم) فمن الممكن علاجك بأدوية لخفض ضغط الدم. ينبغي على طبيبك أن يتأكد من أن مستوى ضغط دمك تحت السيطرة قبل البدء في العلاج بإنليتا، وأثناء العلاج بهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من مشكلات في الغدة الدرقية</strong><strong>.</strong><br />يمكن لإنليتا أن يتسبب في مشكلات في الغدة الدرقية. أخبر طبيبك إذا كنت تتعب بسهولة أكبر، وتشعر بالبرودة أكثر من الأشخاص الآخرين بشكل عام، أو إذا كان صوتك يزداد عمقًا خلال فترة تناول هذا الدواء. ينبغي فحص وظيفة الغدة الدرقية قبل تناول إنليتا وبشكل منتظم بعد ذلك أثناء العلاج به. إذا لم تكن الغدة الدرقية تنتج هرمونًا درقيًا كافيًا من قبل العلاج بهذا الدواء أو أثناء العلاج به، ينبغي أن تُعالَج ببديل للهرمون الدرقي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت قد واجهت مؤخرًا مشاكل تكون الجلطات الدموية في أوردتك وشرايينك (أنواع الأوعية الدموية) بما في ذلك السكتة الدماغية أو الأزمة القلبية أو الانسداد أو الجلطة. </strong></p><p dir="RTL">اسع للحصول على مساعدة طارئة على الفور واتصل بطبيبك إذا ظهرت عليك أعراض مثل ألم أو ضغط بالصدر؛ أو ألم بذراعيك أو ظهرك أو رقبتك أو فكك؛ أو ضيق التنفس؛ أو خدر أو ضعف في جانب واحد من جسمك؛ أو مشكلة في الكلام؛ أو صداع؛ أو تغيرات في الرؤية أو دوار أثناء فترة العلاج بهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من مشاكل النزيف.</strong></p><p dir="RTL">يمكن لإنليتا أن يزيد من فرص حدوث نزيف. أخبر طبيبك في حال حدوث نزيف أو إخراج دماء أثناء السعال أو بصاق ممزوج بدم أثناء فترة العلاج بهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كنت مصابًا أو سبق أن أصبت بأم الدم (تضخم وضعف بجدار وعاء دموي) أو تمزق بجدار وعاء دموي.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا عانيت من آلام حادة في المعدة (البطن) أو ألم في البطن لا يزول أثناء فترة علاجك بهذا الدواء.</strong></p><p dir="RTL">يمكن لإنليتا أن يزيد من خطر حدوث ثقب في المعدة أو الأمعاء أو تكون الناسور (قناة غير طبيعية على شكل أنبوب تصل بين تجويف طبيعي واحد بالجسم وتجويف آخر بالجسم أو الجلد).<br />أخبر طبيبك إذا عانيت من ألم حاد في البطن أثناء فترة علاجك بهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت ستخضع لعملية جراحية أو إذا كان لديك جرح لم يلتئم بعد.</strong><br />ينبغي على طبيبك إيقاف العلاج بإنليتا لمدة ۲٤ ساعة على الأقل قبل موعد إجراء العملية حيث يمكن لإنليتا أن يؤثر على عملية التئام الجرح. ينبغي استئناف علاجك بهذا الدواء مرة أخرى عند التئام الجرح بالشكل المناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا ظهرت عليك أعراض مثل الصداع أو التشوش أو النوبات أو تغيرات في الرؤية مع أو بدون ضغط دم مرتفع، أثناء فترة العلاج بهذا الدواء.</strong></p><p dir="RTL">فاحصل على مساعدة طارئة على الفور واتصل بطبيبك. قد يكون هذا من الآثار الجانبية العصبية النادرة التي تسمى بمتلازمة اعتلال بيضاء الدماغ الخلفي القابلة للانعكاس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من مشكلات الكبد.</strong></p><p dir="RTL">ينبغي على طبيبك إجراء اختبارات دم لفحص وظائف الكبد قبل وأثناء العلاج بإنليتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا عانيت من أعراض مثل الشعور بالإرهاق الزائد أو تورم البطن أو الساقين أو الكاحلين أو ضيق التنفس أو بروز أوردة الرقبة، أثناء العلاج بهذا الدواء.</strong></p><p dir="RTL">قد يزيد إنليتا من خطر وقوع أحداث الفشل القلبي. ينبغي على طبيبك مراقبتك لاكتشاف علامات أو أعراض أحداث الفشل القلبي بشكل دوري خلال فترة علاجك بأكسيتينيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong></p><p dir="RTL">لا يوصى باستعمال إنليتا للأشخاص أقل من ۱۸ سنة. لم تتم دراسة هذا الدواء في الأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج -</strong><strong> </strong><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">قد تؤثر بعض الأدوية على إنليتا أو تتأثر به. برجاء إخبار طبيبك أو الصيدلي أو الممرضة عن جميع الأدوية التي تناولتها مؤخرًا أو تتناولها حاليًا أو تنوي تناولها، بما في ذلك الأدوية التي لا تحتاج إلى وصفة طبية والفيتامينات والأدوية العشبية. قد لا تكون الأدوية المُدرجة في هذه النشرة هي الوحيدة التي يمكن أن تتفاعل مع إنليتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تُزيد الأدوية التالية من خطر حدوث آثار جانبية عند استعمالها مع إنليتا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول أو إيتراكونازول، يستخدم لعلاج العدوى الفطرية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلاريثروميسين أو إريثروميسين أو تليثرومايسين، مضادات حيوية تستخدم لعلاج العدوى البكتيرية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أتازانافير أو إندينافير أو نيلفينافير أو ريتونافير أو ساكينافير، والتي تستخدم لعلاج عدوى فيروس نقص المناعة البشرية/الإيدز؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفازودون، يستخدم لعلاج الاكتئاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤدي العقاقير التالية إلى تقليل فعالية إنليتا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين أو ريفابوتين أو ريفابنتين، والتي تستخدم لعلاج السل TB))؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديكساميثازون، دواء ستيرويدي يوصف لعلاج العديد من الحالات المختلفة، بما في ذلك الأمراض الخطيرة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين أو كاربامازيبين أو فينوباربيتال، مضادات صرع تستخدم لوقف النوبات؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (<em>هايبريكوم بيرفوراتوم</em>)، منتج عشبي يستخدم لعلاج الاكتئاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>&nbsp;</em><strong>ينبغي عدم</strong> تناول هذه الأدوية<em> </em>أثناء علاجك بإنليتا. إذا كنت تتناول أيًا منها، فأخبر الطبيب أو الصيدلي أو الممرضة. قد يغير الطبيب جرعة هذه الأدوية أو جرعة إنليتا أو يصف لك دواءً آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزيد إنليتا من الآثار الجانبية المصاحبة لثيوفيلين، والذي يستخدم لعلاج الربو أو الأمراض الرئوية الأخرى.</p><p dir="RTL"><strong>د &ndash; تناول إنليتا مع الطعام والشراب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول هذا الدواء مع الجريب فروت أو عصير الجريب فروت، حيث أنه يمكن أن يزيد من فرص حدوث الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ه</strong><strong>ـ</strong><strong> - الحمل والرضاعة </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنك ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي أو الممرضة قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يلحق إنليتا الأذى بالأجنة أو الأطفال الذين يرضعون رضاعة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناولي هذا الدواء أثناء الحمل. تحدثي إلى الطبيب الخاص بكِ قبل تناوله إذا كنتِ حاملًا أو قد تصبحين حاملاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدمي وسيلة موثوقة لمنع الحمل أثناء تناول إنليتا وحتى أسبوع بعد آخر جرعة من هذا الدواء، لمنع حدوث حمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ترضعي طفلك رضاعة طبيعية أثناء العلاج بإنليتا. إذا كنت تُرضعين رضاعة طبيعية، فينبغي على طبيبك مناقشتك فيما إذا كنت ستوقفين الرضاعة أم توقفين العلاج بإنليتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>و &ndash; </em></strong><strong>تأثير</strong><strong> </strong><strong>إنليتا على القيادة</strong><strong> واستخدام الآلات</strong></p><p dir="RTL">إذا شعرت بالدوار و/أو التعب أثناء العلاج بإنليتا، فتوخ الحذر بشكل خاص عند القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ز- معلومات هامة حول بعض مكونات إنليتا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي إنليتا</strong> <strong>على اللاكتوز </strong></p><p dir="RTL">إذا أخبرك طبيبك أنك لا تستطيع تحمل بعض السكريات، فاتصل به قبل تناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي </strong><strong>إنليتا على صوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من ۱ مليمول من الصوديوم (۲۳ ملجم) في كل قرص مغلف بطبقة رقيقة، وهذا يعني أنه &quot;خال من الصوديوم&quot; تقريبًا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دومًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. ينبغي أن تتحقق من طبيبك أو الصيدلي أو الممرضة إذا لم تكن متأكدًا مما ينبغي عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي 5 ملجم مرتين يوميًا. قد يقوم الطبيب فيما بعد بزيادة أو تقليل الجرعة الخاصة بك وفقًا لكيفية تحملك العلاج باستخدام إنليتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ابتلع الأقراص كاملةً بالماء، مع الطعام أو دونه. تناول جرعات إنليتا كل 12 ساعة تقريبًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ &ndash; الجرعة الزائدة من إنليتا</strong></p><p dir="RTL">إذا تناولت بالخطأ الكثير من الأقراص أو جرعة أكبر مما تحتاج إليه، فاتصل بطبيب لاستشارته على الفور. اعرض العبوة أو هذه النشرة الطبية على الطبيب إن أمكن. قد تحتاج إلى رعاية طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب - نسيان تناول جرعة إنليتا</strong></p><p dir="RTL">تناول جرعتك التالية في الوقت المحدد لها. لا تتناول جرعة مزدوجة لتعويض الأقراص التي نسيتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج &ndash; التوقف عن تناول إنليتا</strong></p><p dir="RTL">إذا تقيأت، ينبغي ألا تتناول جرعة إضافية. ولكن ينبغي أن تتناول الجرعة التالية الموصوفة في موعدها المُعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن تناول إنليتا</strong></p><p dir="RTL">إذا لم تستطع تناول هذا الدواء كما وصفه طبيبك أو إذا شعرت أنك لم تعد تحتاج إليه، فاتصل بطبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية اسئلة أخرى حول استخدام هذا الدواء، فتوجه بها إلى طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء أعراضًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تكون بعض الأعراض الجانبية خطيرة. يجب عليك التواصل مع طبيبك على الفور إذا عانيت من أي من الأعراض الجانبية الخطيرة التالية (انظر أيضًا القسم 2 &quot;ما يتعين عليك معرفته قبل تناول إنليتا&quot;):</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أحداث الفشل القلبي. </strong>أخبر طبيبك إذا عانيت من الشعور بالإرهاق الزائد أو تورم البطن أو الساقين أو الكاحلين أو ضيق التنفس أو بروز أوردة الرقبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تكون الجلطات الدموية في أوردتك وشرايينك (أنواع من الأوعية الدموية) بما في ذلك السكتة الدماغية أو الأزمة القلبية أو الانسداد الوعائي الدموي أو الجلطة.</strong> احصل على مساعدة طارئة على الفور واتصل بطبيبك إذا ظهرت عليك أعراض مثل ألم أو ضغط بالصدر؛ أو ألم بذراعيك أو ظهرك أو رقبتك أو فكك؛ أو ضيق التنفس؛ أو خدر أو ضعف في جانب واحد من جسمك؛ أو صعوبة في الكلام؛ أو صداع؛ أو تغيرات في الرؤية؛ أو دوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>النزيف. </strong>أخبر طبيبك على الفور إذا ظهرت عليك أي من هذه الأعراض أو مشكلة نزيف خطيرة خلال فترة علاجك باستخدام إنليتا: براز أسود اللون يشبه القطران أو إخراج دماء أثناء السعال أو بصاق ممزوج بمخاط ودم أو تغير في حالتك الذهنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ثقب في المعدة أو الأمعاء أو تكون الناسور (قناة غير طبيعية على شكل أنبوب تصل بين تجويف طبيعي واحد بالجسم وتجويف آخر بالجسم أو الجلد).</strong> أخبر طبيبك إذا شعرت بألم شديد بالبطن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ارتفاع شديد في ضغط الدم (نوبة ارتفاع ضغط الدم).</strong> أخبر طبيبك إذا كنت تعاني من ضغط الدم المرتفع للغاية أو من الصداع الشديد أو من ألم شديد بالصدر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تورم المخ بشكل قابل للانعكاس (متلازمة الاعتلال الدماغي الخلفي القابلة للانعكاس).</strong> احصل على مساعدة طارئة على الفور واتصل بطبيبك إذا ظهرت عليك أعراض مثل الصداع أو التشوش أو النوبات أو تغيرات في الرؤية مع أو بدون ضغط دم مرتفع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتضمن الآثار الجانبية الأخرى لإنليتا:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا: قد تؤثر على أكثر من فرد واحد بين كل 10 أفراد</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المرتفع أو ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، أن تشعر بالغثيان أو القيء أو تتقيأ بالفعل، ألم بالمعدة، عسر الهضم، مرارة الفم أو اللسان أو الحلق، الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، السعال، خشونة في الصوت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الطاقة أو الشعور بالضعف أو التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور نشاط الغدة الدرقية (قد يظهر في اختبارات الدم الخاصة بك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار وتورم في راحتي اليدين أو في أخمص القدمين (متلازمة اليد-القدم)، الطفح الجلدي، جفاف الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل أو ألم في اليدين أو القدمين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود بروتين في البول (قد يظهر في اختبارات البول الخاصة بك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع أو اضطراب حس التذوق أو فقدان حس التذوق</p><p dir="RTL"><strong>شائعة: قد تؤثر على ما يصل إلى شخص واحد بين كل 10 أشخاص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف (فقدان سوائل الجسم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; امتلاء البطن بالغازات، البواسيرنزيف من اللثة، نزيف من المستقيم، إحساس بالحرق أو إحساس لاذع في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية (قد تظهر في اختبارات الدم الخاصة بك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتقان الحلق أو الأنف وتهيج الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة الجلد، احمرار الجلد، سقوط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين/صوت بالأذن (طنين الأذن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة عدد خلايا الدم الحمراء (قد تظهر في اختبارات الدم الخاصة بك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة عدد الصفائح الدموية (خلايا تساعد على تجلط الدم) (قد تظهر في اختبارات الدم الخاصة بك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود خلايا دم حمراء في البول (قد تظهر في اختبارات البول الخاصة بك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في مستويات المواد الكيميائية/الإنزيمات المختلفة في الدم (قد تظهر في اختبارات الدم الخاصة بك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة عدد خلايا الدم الحمراء (قد تظهر في اختبارات الدم الخاصة بك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم البطن أو الساقين أو الكاحلين، بروز أوردة الرقبة، الشعور بالإرهاق الزائد، ضيق التنفس (علامات على أحداث الفشل القلبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الناسور (قناة غير طبيعية على شكل أنبوب تصل بين تجويف طبيعي واحد بالجسم وتجويف آخر بالجسم أو الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحويصلة الصفراوية (المرارة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: قد تؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong>قلة عدد خلايا الدم البيضاء (قد تظهر في اختبارات الدم الخاصة بك)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة: </strong><strong>لا يمكن تقدير معدل تكرارها من البيانات المتاحة</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تضخم وضعف بجدار وعاء دموي أو تمزق بجدار وعاء دموي (حالات أم الدم وتسلخ الشرايين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>5. </strong><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL">إذا ظهرت عليك أي آثار جانبية، فتحدث إلى طبيبك ، الصيدلي أو الممرضة. يشمل هذا أي آثار جانبية محتملة وغير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء</p><p dir="RTL"><strong><em>&middot;&nbsp;</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp; </em></strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ الدوائي</strong><strong> </strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهاتف مركز الاتصال: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>&nbsp;</em></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: <u>www.sfda.gov.sa/npc</u></p><p dir="RTL"><strong><em>&nbsp;</em></strong></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المكتوب على العبوة الكرتونية وعلى أشرطة البليستر المصنوعة من رقائق معدنية أو الزجاجة بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي تخزين هذا الدواء في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم أي عبوة تالفة أو تظهر عليها علامات عبث.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي أكسيتينيب. أقراص إنليتا المغلفة بطبقة رقيقة تأتي في تركيزات مختلفة.</p><p dir="RTL">إنليتا 1 ملجم: يحتوي كل قرص على 1 ملجم من أكسيتينيب</p><p dir="RTL">إنليتا 5 ملجم: يحتوي كل قرص على 5 ملجم من أكسيتينيب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي سليلوز دقيق التبلور ، لاكتوز أحادي الهيدرات، كروسكارميلوز الصوديوم، ستيارات المغنيسيوم، هيبروميلوز 2910 &nbsp;(15 ميللي باسكال.ثانية)، ثاني أكسيد التيتانيوم (E171)، ثلاثي الأستين (E1518)، أكسيد الحديد الأحمر (E172) (انظر القسم 2 يحتوي إنليتا على اللاكتوز (سكر اللبن)).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أقراص إنليتا 1 ملجم المغلفة بطبقة رقيقة حمراء اللون بيضاوية ومحفور عليها &quot;Pfizer&quot; على جانب و&quot;1 XNB&quot; على الجانب الآخر. إنليتا 1 ملجم متاح في زجاجات تحتوي على 180 قرصًا وأشرطة تحتوي على 14 قرصًا. كل عبوة من عبوات الأشرطة تحتوي على 28 قرصًا أو 56 قرصًا.</strong></p><p dir="RTL"><strong>تحتوي عبوة ال56 قرصاً ، على 4 شرائط يحتوي كل شريط على 14 قرص مغلف بطبقة رقيقة (14&nbsp; X4.</strong><strong>)</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أقراص إنليتا 5 ملجم المغلفة بطبقة رقيقة حمراء اللون مثلثة الشكل ومحفور عليها &quot;Pfizer&quot; على جانب و&quot;5 XNB&quot; على الجانب الآخر. إنليتا 5 ملجم متاح في أشرطة تحتوي على 14 قرصًا. كل عبوة من عبوات الأشرطة تحتوي على 28 قرصًا أو 56 قرصًا.</strong></p><p dir="RTL"><strong>تحتوي عبوة ال56 قرصاً ، على 4 شرائط يحتوي كل شريط على 14 قرص مغلف بطبقة رقيقة (14 X4.)</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تُطرح جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك تصريح التسويق</strong></p><p>&nbsp;</p><p>Pfizer Limited</p><p>Ramsgate Road</p><p>Sandwich, Kent CT13&nbsp;9NJ</p><p>United Kingdom، المملكة المتحدة</p><p>&nbsp;</p><p><strong>الجهة المصنعة </strong></p><p>&nbsp;</p><p>Pfizer Manufacturing Deutschland GmbH</p><p>Betriebsst&auml;tte Freiburg</p><p>Mooswaldallee 1</p><p>79090 Freiburg</p><p>Germany،</p><p>&nbsp;ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اكتوبر 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inlyta 1 mg film-coated tablets
Inlyta 5 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inlyta 1 mg film-coated tablets
Each film-coated tablet contains 1 mg of axitinib.


Inlyta 5 mg film-coated tablets
Each film-coated tablet contains 5 mg of axitinib.


Excipients with known effect

Inlyta 1 mg film-coated tablet
Each film-coated tablet contains 33.6 mg of lactose monohydrate.


Inlyta 5 mg film-coated tablet
Each film-coated tablet contains 58.8 mg of lactose monohydrate.


For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Inlyta 1 mg film-coated tablets
Red oval film-coated tablet debossed with “Pfizer” on one side and “1 XNB” on the other.


Inlyta 5 mg film-coated tablets
Red triangular film-coated tablet debossed with “Pfizer” on one side and “5 XNB” on the other.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Inlyta should be conducted by a physician experienced in the use of anticancer therapies.</p><p>&nbsp;</p><p><u>Posology</u></p><p><em><u>&nbsp;</u></em></p><p>The recommended dose of axitinib is 5&nbsp;mg twice daily.</p><p>&nbsp;</p><p>Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs that cannot be managed by concomitant medicinal products or dose adjustments.</p><p><strong><em>&nbsp;</em></strong></p><p>If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.</p><p>&nbsp;</p><p><em><u>Dose adjustments</u></em></p><p><em><u>&nbsp;</u></em></p><p>Dose increase or reduction is recommended based on individual safety and tolerability.</p><p>&nbsp;</p><p>Patients who tolerate the axitinib starting dose of 5&nbsp;mg twice daily with no adverse reactions &gt;&nbsp;Grade&nbsp;2 (i.e. without severe adverse reactions according to the Common Terminology Criteria for Adverse Events [CTCAE] version&nbsp;3.0) for two consecutive weeks may have their dose increased to 7&nbsp;mg twice daily unless the patient&rsquo;s blood pressure is &gt;&nbsp;150/90&nbsp;mmHg or the patient is receiving antihypertensive treatment. Subsequently, using the same criteria, patients who tolerate an axitinib dose of 7&nbsp;mg twice daily may have their dose increased to a maximum of 10&nbsp;mg twice daily.</p><p>&nbsp;</p><p>Management of some adverse reactions may require temporary or permanent discontinuation and/or dose reduction of axitinib therapy (see section&nbsp;4.4). When dose reduction is necessary, the axitinib dose may be reduced to 3&nbsp;mg twice daily and further to 2&nbsp;mg twice daily.</p><p>&nbsp;</p><p>Dose adjustment is not required on the basis of patient age, race, gender, or body weight.</p><p>&nbsp;</p><p><em>Concomitant strong CYP3A4/5 inhibitors</em></p><p>Co-administration of axitinib with strong CYP3A4/5 inhibitors may increase axitinib plasma concentrations (see section&nbsp;4.5). Selection of an alternate concomitant medicinal product with no or minimal CYP3A4/5 inhibition potential is recommended.</p><p>&nbsp;</p><p>Although axitinib dose adjustment has not been studied in patients receiving strong CYP3A4/5&nbsp;inhibitors, if a strong CYP3A4/5 inhibitor must be co-administered, a dose decrease of axitinib to approximately half the dose (e.g. the starting dose should be reduced from 5&nbsp;mg twice daily to 2&nbsp;mg twice daily) is recommended. Management of some adverse reactions may require temporary or permanent discontinuation of axitinib therapy (see section&nbsp;4.4). If co-administration of the strong inhibitor is discontinued, a return to the axitinib dose used prior to initiation of the strong CYP3A4/5&nbsp;inhibitor should be considered (see section&nbsp;4.5).</p><p><em>&nbsp;</em></p><p><em>Concomitant strong CYP3A4/5 inducers</em></p><p>Co-administration of axitinib with strong CYP3A4/5&nbsp;inducers may decrease axitinib plasma concentrations (see section&nbsp;4.5). Selection of an alternate concomitant medicinal product with no or minimal CYP3A4/5&nbsp;induction potential is recommended.</p><p>&nbsp;</p><p>Although axitinib dose adjustment has not been studied in patients receiving strong CYP3A4/5&nbsp;inducers, if a strong CYP3A4/5 inducer must be co-administered, a gradual dose increase of axitinib is recommended. Maximal induction with high-dose strong CYP3A4/5 inducers has been reported to occur within one week of treatment with the inducer. If the dose of axitinib is increased, the patient should be monitored carefully for toxicity. Management of some adverse reactions may require temporary or permanent discontinuation and/or dose reduction of axitinib therapy (see section&nbsp;4.4). If co-administration of the strong inducer is discontinued, the axitinib dose should be immediately returned to the dose used prior to initiation of the strong CYP3A4/5 inducer (see section&nbsp;4.5).</p><p><em>&nbsp;</em></p><p><em><u>Special populations</u></em></p><p><strong><em>&nbsp;</em></strong></p><p><em>Elderly (&ge;&nbsp;65 years)</em></p><p>No dose adjustment is required (see sections&nbsp;4.4 and&nbsp;5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required (see section&nbsp;5.2). Virtually no data are available regarding axitinib treatment in patients with a creatinine clearance of &lt;&nbsp;15 mL/min.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is required when administering axitinib to patients with mild hepatic impairment (Child-Pugh class&nbsp;A). A dose decrease is recommended when administering axitinib to patients with moderate hepatic impairment (Child-Pugh class&nbsp;B) (e.g. the starting dose should be reduced from 5&nbsp;mg twice daily to 2&nbsp;mg twice daily). Axitinib has not been studied in patients with severe hepatic impairment (Child-Pugh class&nbsp;C) and should not be used in this population (see sections&nbsp;4.4 and&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Inlyta in children and adolescents &lt;&nbsp;18 years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><em><u>&nbsp;</u></em></p><p>Axitinib is for oral use. The tablets should be taken orally twice daily approximately 12&nbsp;hours apart with or without food (see section&nbsp;5.2). They should be swallowed whole with a glass of water.</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to axitinib or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Specific safety events should be monitored before initiation of, and periodically throughout, treatment with axitinib as described below.</p><p>&nbsp;</p><p><u>Cardiac failure events</u></p><p>In clinical studies with axitinib for the treatment of patients with RCC, cardiac failure events (including cardiac failure, cardiac failure congestive, cardiopulmonary failure, left ventricular dysfunction, ejection fraction decreased, and right ventricular failure) were reported (see section 4.8).</p><p>&nbsp;</p><p>Signs or symptoms of cardiac failure should periodically be monitored throughout treatment with axitinib. Management of cardiac failure events may require temporary interruption or permanent discontinuation and/or dose reduction of axitinib therapy.</p><p><em>&nbsp;</em></p><p><u>Hypertension</u></p><p>In clinical studies with axitinib for the treatment of patients with RCC, hypertension was very commonly reported (see section&nbsp;4.8).</p><p>&nbsp;</p><p>In a controlled clinical study, the median onset time for hypertension (systolic blood pressure &gt;&nbsp;150&nbsp;mmHg or diastolic blood pressure &gt;&nbsp;100&nbsp;mmHg) was within the first month of the start of axitinib treatment and blood pressure increases have been observed as early as 4 days after starting axitinib.</p><p>&nbsp;</p><p>Blood pressure should be well-controlled prior to initiating axitinib. Patients should be monitored for hypertension and treated as needed with standard antihypertensive therapy. In the case of persistent hypertension, despite use of antihypertensive medicinal products, the axitinib dose should be reduced. For patients who develop severe hypertension, temporarily interrupt axitinib and restart at a lower dose once the patient is normotensive. If axitinib is interrupted, patients receiving antihypertensive medicinal products should be monitored for hypotension (see section&nbsp;4.2).</p><p>&nbsp;</p><p>In case of severe or persistent arterial hypertension and symptoms suggestive of posterior reversible encephalopathy syndrome (PRES) (see below), a diagnostic brain magnetic resonance image (MRI) should be considered.</p><p>&nbsp;</p><p><u>Thyroid dysfunction</u></p><p>In clinical studies with axitinib for the treatment of patients with RCC, events of hypothyroidism and, to a lesser extent, hyperthyroidism, were reported (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Thyroid function should be monitored before initiation of, and periodically throughout, treatment with axitinib. Hypothyroidism or hyperthyroidism should be treated according to standard medical practice to maintain euthyroid state.</p><p>&nbsp;</p><p><u>Arterial embolic and thrombotic events</u></p><p>In clinical studies with axitinib, arterial embolic and thrombotic events (including transient ischemic attack, myocardial infarction, cerebrovascular accident and retinal artery occlusion) were reported (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Axitinib should be used with caution in patients who are at risk for, or who have a history of, these events. Axitinib has not been studied in patients who had an arterial embolic or thrombotic event within the previous 12 months.</p><p>&nbsp;</p><p><u>Venous embolic and thrombotic events</u></p><p>In clinical studies with axitinib, venous embolic and thrombotic events (including pulmonary embolism, deep vein thrombosis, and retinal vein occlusion/thrombosis) were reported (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Axitinib should be used with caution in patients who are at risk for, or who have a history of, these events. Axitinib has not been studied in patients who had a venous embolic or thrombotic event within the previous 6 months.</p><p><em>&nbsp;</em></p><p><u>Elevation of haemoglobin or haematocrit</u></p><p>Increases in haemoglobin or haematocrit, reflective of increases in red blood cell mass, may occur during treatment with axitinib (see section&nbsp;4.8, polycythaemia). An increase in red blood cell mass may increase the risk of embolic and thrombotic events.</p><p>&nbsp;</p><p>Haemoglobin or haematocrit should be monitored before initiation of, and periodically throughout, treatment with axitinib. If haemoglobin or haematocrit becomes elevated above the normal level, patients should be treated according to standard medical practice to decrease haemoglobin or haematocrit to an acceptable level.</p><p>&nbsp;</p><p><u>Haemorrhage</u></p><p>In clinical studies with axitinib, haemorrhagic events were reported (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Axitinib has not been studied in patients who have evidence of untreated brain metastasis or recent active gastrointestinal bleeding, and should not be used in those patients. If any bleeding requires medical intervention, temporarily interrupt the axitinib dose.</p><p>&nbsp;</p><p><u>Aneurysms and artery dissections</u></p><p>The use of VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysms and/or artery dissections. Before initiating Inlyta, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.</p><p>&nbsp;</p><p><u>Gastrointestinal perforation</u><u> and fistula formation</u></p><p>In clinical studies with axitinib, events of gastrointestinal perforation and fistulas were reported (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Symptoms of gastrointestinal perforation or fistula should be periodically monitored for throughout treatment with axitinib.</p><p><em>&nbsp;</em></p><p><u>Wound healing complications</u></p><p>No formal studies of the effect of axitinib on wound healing have been conducted.</p><p>&nbsp;</p><p>Treatment with axitinib should be stopped at least 24 hours prior to scheduled surgery. The decision to resume axitinib therapy after surgery should be based on clinical judgment of adequate wound healing.</p><p><em>&nbsp;</em></p><p><u>Posterior reversible encephalopathy syndrome (PRES)</u></p><p>In clinical studies with axitinib, events of PRES were reported (see section&nbsp;4.8).</p><p>&nbsp;</p><p>PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances. Mild to severe hypertension may be present. Magnetic resonance imaging is necessary to confirm the diagnosis of PRES. In patients with signs or symptoms of PRES, temporarily interrupt or permanently discontinue axitinib treatment. The safety of reinitiating axitinib therapy in patients previously experiencing PRES is not known.</p><p>&nbsp;</p><p><u>Proteinuria</u></p><p>In clinical studies with axitinib, proteinuria, including that of Grade&nbsp;3 and 4 severity, was reported (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Monitoring for proteinuria before initiation of, and periodically throughout, treatment with axitinib is recommended. For patients who develop moderate to severe proteinuria, reduce the dose or temporarily interrupt axitinib treatment (see section&nbsp;4.2). Axitinib should be discontinued if the patient develops nephrotic syndrome.</p><p><em>&nbsp;</em></p><p><u>Liver-related adverse reactions</u></p><p>In a controlled clinical study with axitinib for the treatment of patients with RCC, liver-related adverse reactions were reported. The most commonly reported liver-related adverse reactions included increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood bilirubin (see section&nbsp;4.8). No concurrent elevations of ALT (&gt;&nbsp;3&nbsp;times the upper limit of normal [ULN]) and bilirubin (&gt;&nbsp;2&nbsp;times the ULN) were observed.</p><p>&nbsp;</p><p>In a clinical dose-finding study, concurrent elevations of ALT (12&nbsp;times the ULN) and bilirubin (2.3&nbsp;times the ULN), considered to be drug-related hepatotoxicity, were observed in 1 patient who received axitinib at a starting dose of 20&nbsp;mg twice daily (4&nbsp;times the recommended starting dose).</p><p>&nbsp;</p><p>Liver function tests should be monitored before initiation of, and periodically throughout, treatment with axitinib.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Hepatic impairment</u></p><p>In clinical studies with axitinib, the systemic exposure to axitinib was approximately two‑fold higher in subjects with moderate hepatic impairment (Child-Pugh class&nbsp;B) compared to subjects with normal hepatic function. A dose decrease is recommended when administering axitinib to patients with moderate hepatic impairment (Child-Pugh class&nbsp;B) (see section&nbsp;4.2).<br />&nbsp;</p><p>Axitinib has not been studied in patients with severe hepatic impairment (Child-Pugh class&nbsp;C) and should not be used in this population.</p><p>&nbsp;</p><p><u>Elderly (&ge;&nbsp;65 years) and race</u></p><p>In a controlled clinical study with axitinib for the treatment of patients with RCC, 34% of patients treated with axitinib were &ge;&nbsp;65 years of age. The majority of patients were White&nbsp;(77%) or Asian&nbsp;(21%). Although greater sensitivity to develop adverse reactions in some older patients and Asian patients cannot be ruled out, overall, no major differences were observed in the safety and effectiveness of axitinib between patients who were &ge;&nbsp;65 years of age and non-elderly, and between White patients and patients of other races.</p><p>&nbsp;</p><p>No dosage adjustment is required on the basis of patient age or race (see sections&nbsp;4.2 and&nbsp;5.2).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p><u>Lactose</u></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p><em><u>Sodium</u></em></p><p>This medicinal product contains less than 1&nbsp;mmol (23 mg) sodium per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em> data indicate that axitinib is metabolised primarily by CYP3A4/5 and, to a lesser extent, CYP1A2, CYP2C19, and uridine diphosphate-glucuronosyltransferase (UGT) 1A1.</p><p><em>&nbsp;</em></p><p><u>CYP3A4/5 inhibitors</u></p><p>Ketoconazole, a strong inhibitor of CYP3A4/5, administered at a dose of 400&nbsp;mg once daily for 7&nbsp;days, increased the mean area under the curve (AUC) 2‑fold and C<sub>max</sub> 1.5‑fold of a single 5-mg oral dose of axitinib in healthy volunteers. Co-administration of axitinib with strong CYP3A4/5 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, erythromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin) may increase axitinib plasma concentrations. Grapefruit may also increase axitinib plasma concentrations. Selection of concomitant medicinal products with no or minimal CYP3A4/5 inhibition potential is recommended. If a strong CYP3A4/5&nbsp;inhibitor must be co-administered, a dose adjustment of axitinib is recommended (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>CYP1A2 and CYP2C19 inhibitors</u></p><p>CYP1A2 and CYP2C19 constitute minor (&lt;&nbsp;10%) pathways in axitinib metabolism. The effect of strong inhibitors of these isozymes on axitinib pharmacokinetics has not been studied. Caution should be exercised due to the risk of increased axitinib plasma concentrations in patients taking strong inhibitors of these isozymes.</p><p><em>&nbsp;</em></p><p><u>CYP3A4/5 inducer</u><u>s</u></p><p>Rifampicin, a strong inducer of CYP3A4/5, administered at a dose of 600&nbsp;mg once daily for 9&nbsp;days, reduced the mean AUC by 79% and C<sub>max</sub> by 71% of a single 5&nbsp;mg dose of axitinib in healthy volunteers.</p><p>&nbsp;</p><p>Co-administration of axitinib with strong CYP3A4/5 inducers (e.g. rifampicin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and <em>Hypericum perforatum</em> [St. John&rsquo;s wort]) may decrease axitinib plasma concentrations. Selection of concomitant medicinal products with no or minimal CYP3A4/5 induction potential is recommended. If a strong CYP3A4/5 inducer must be co-administered, a dose adjustment of axitinib is recommended (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>In vitro studies of CYP and UGT inhibition and induction</u></p><p><em>In vitro</em> studies indicated that axitinib does not inhibit CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, or UGT1A1 at therapeutic plasma concentrations.</p><p><em>&nbsp;</em></p><p><em>In vitro</em> studies indicated that axitinib has a potential to inhibit CYP1A2. Therefore, co-administration of axitinib with CYP1A2 substrates may result in increased plasma concentrations of CYP1A2&nbsp;substrates (e.g. theophylline).</p><p><em>&nbsp;</em></p><p><em>In vitro</em> studies also indicated that axitinib has the potential to inhibit CYP2C8. However, co‑administration of axitinib with paclitaxel, a known CYP2C8 substrate, did not result in increased plasma concentrations of paclitaxel in patients with advanced cancer, indicating lack of clinical CYP2C8 inhibition.</p><p><em>&nbsp;</em></p><p><em>In vitro</em> studies in human hepatocytes also indicated that axitinib does not induce CYP1A1, CYP1A2, or CYP3A4/5. Therefore co-administration of axitinib is not expected to reduce the plasma concentration of co-administered CYP1A1, CYP1A2, or CYP3A4/5 substrates <em>in vivo</em>.</p><p><em>&nbsp;</em></p><p><u>In vitro studies with P-glycoprotein</u></p><p><em>In vitro</em> studies indicated that axitinib inhibits P-glycoprotein. However, axitinib is not expected to inhibit P-glycoprotein at therapeutic plasma concentrations. Therefore, co-administration of axitinib is not expected to increase the plasma concentration of digoxin, or other P-glycoprotein substrates, <em>in&nbsp;vivo</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data regarding the use of axitinib in pregnant women. Based on the pharmacological properties of axitinib, it may cause foetal harm when administered to a pregnant woman. Studies in animals have shown reproductive toxicity including malformations (see section&nbsp;5.3). Axitinib should not be used during pregnancy unless the clinical condition of the woman requires treatment with this medicinal product.</p><p>&nbsp;</p><p>Women of childbearing potential must use effective contraception during and up to 1&nbsp;week after treatment.</p><p><em>&nbsp;</em></p><p><u>Breast-feeding</u></p><p>It is unknown whether axitinib is excreted in human milk. A risk to the suckling child cannot be excluded. Axitinib should not be used during breast-feeding.</p><p><em>&nbsp;</em></p><p><u>Fertility</u></p><p>Based on non-clinical findings, axitinib has the potential to impair reproductive function and fertility in humans (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Axitinib has minor influence on the ability to drive and use machines. Patients should be advised that they may experience events such as dizziness and/or fatigue during treatment with axitinib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The following risks, including appropriate action to be taken, are discussed in greater detail in section&nbsp;4.4: cardiac failure events, hypertension, thyroid dysfunction, arterial thromboembolic events, venous thromboembolic events, elevation of haemoglobin or haematocrit, haemorrhage, gastrointestinal perforation and fistula formation, wound healing complications, PRES, proteinuria, and elevation of liver enzymes.</p><p>&nbsp;</p><p>The most common (&ge;&nbsp;20%) adverse reactions observed following treatment with axitinib were diarrhoea, hypertension, fatigue, decreased appetite, nausea, weight decreased, dysphonia, palmar‑plantar erythrodysaesthesia (hand-foot) syndrome, haemorrhage, hypothyroidism, vomiting, proteinuria, cough, and constipation.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Table&nbsp;1 presents adverse reactions reported in a pooled dataset of 672 patients who received axitinib in clinical studies for the treatment of patients with RCC (see section&nbsp;5.1). Post-marketing adverse reactions identified in clinical studies are also included.</p><p>&nbsp;</p><p>The adverse reactions are listed by system organ class, frequency category and grade of severity. Frequency categories are defined as: very common (&sup3;&nbsp;1/10), common (&sup3;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&sup3;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&sup3;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000), and not known (cannot be estimated from the available data). The current safety database for axitinib is too small to detect rare and very rare adverse reactions.</p><p>&nbsp;</p><p>Categories have been assigned based on absolute frequencies in the pooled clinical studies data. Within each system organ class, adverse reactions with the same frequency are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1. Adverse reactions reported in RCC studies in patients who received axitinib (N&nbsp;=&nbsp;672)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><thead><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Frequency category</strong></p></td><td><p><strong>Adverse reactions</strong><strong><sup>a</sup></strong></p></td><td><p><strong>All Grades</strong><strong><sup>b</sup></strong></p><p><strong>%</strong></p></td><td><p><strong>Grade 3</strong><strong><sup>b</sup></strong></p><p><strong>%</strong></p></td><td><p><strong>Grade 4</strong><strong><sup>b</sup></strong></p><p><strong>%</strong></p></td></tr></thead><tbody><tr><td rowspan="5" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td rowspan="3" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>6.3</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>0.4</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Polycythaemia<sup>c</sup></p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neutropaenia</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Leukopaenia</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypothyroidism<sup>c</sup></p></td><td style="vertical-align:top"><p>24.6</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperthyroidism<sup>c</sup></p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>39.0</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>3.1</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>16.2</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>11.5</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>9.1</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Posterior reversible encephalopathy syndrome<sup>e</sup></p></td><td style="vertical-align:top"><p>0.3</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>3.1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cardiac failure events<sup>c,d,f</sup></p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Vascular disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypertension<sup>g</sup></p></td><td style="vertical-align:top"><p>51.2</p></td><td style="vertical-align:top"><p>22.0</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>Haemorrhage<sup>c,d,h</sup></p></td><td style="vertical-align:top"><p>25.7</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Venous embolic and thrombotic events<sup>c,d,i</sup></p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>0.9</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Arterial embolic and thrombotic events<sup>c,d,j</sup></p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Aneurysms and artery dissections<sup>d</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Dyspnoea<sup>d</sup></p></td><td style="vertical-align:top"><p>17.1</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>20.4</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dysphonia</p></td><td style="vertical-align:top"><p>32.7</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oropharyngeal pain</p></td><td style="vertical-align:top"><p>7.4</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td rowspan="6" style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>55.4</p></td><td style="vertical-align:top"><p>10.1</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>23.7</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>33.0</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>14.7</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>20.2</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis</p></td><td style="vertical-align:top"><p>15.5</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>11.2</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Upper abdominal pain</p></td><td style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemorrhoids</p></td><td style="vertical-align:top"><p>3.3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Glossodynia</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal perforation and fistula<sup>c,k</sup></p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cholecystitis<sup>n</sup></p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Palmar-plantar erythrodysaesthesia (hand-foot syndrome)</p></td><td style="vertical-align:top"><p>32.1</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>14.3</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>10.1</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>6.0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>17.7</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>14.1</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>8.2</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Proteinuria<sup>l</sup></p></td><td style="vertical-align:top"><p>21.1</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal failure<sup>m</sup></p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>45.1</p></td><td style="vertical-align:top"><p>10.6</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Asthaenia<sup>d</sup></p></td><td style="vertical-align:top"><p>13.8</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Mucosal inflammation</p></td><td style="vertical-align:top"><p>13.7</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>32.7</p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Amylase increased</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.4</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>6.1</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine increased</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Thyroid stimulating hormone increased</p></td><td style="vertical-align:top"><p>7.9</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0</p><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>&nbsp; Adverse reactions are according to treatment-emergent, all causality frequency.</p><p><sup>b&nbsp;&nbsp;&nbsp; </sup>National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0</p><p><sup>c</sup>&nbsp; See Description of selected adverse reactions section.</p><p><sup>d</sup>&nbsp; Fatal (Grade&nbsp;5) cases were reported.</p><p><sup>e&nbsp;&nbsp; </sup>Including Leukoencephalopathy.</p><p><sup>f</sup>&nbsp; Including cardiac failure, cardiac failure congestive, cardiopulmonary failure, ejection fraction decreased, left ventricular dysfunction and right ventricular failure.</p><p><sup>g</sup>&nbsp; Including accelerated hypertension, blood pressure increased, hypertension and hypertensive crisis.</p><p><sup>h</sup>&nbsp; Including activated partial thromboplastin time prolonged, anal haemorrhage, &nbsp;arterial haemorrhage, blood urine present, central nervous system haemorrhage, cerebral haemorrhage, coagulation time prolonged, conjunctival haemorrhage, contusion, diarrhea haemorrhagic, dysfunctional uterine bleeding, epistaxis, gastric haemorrhage, gastrointestinal haemorrhage, gingival bleeding, haematemesis, haematochezia, haematocrit decreased, haematoma, haematuria, haemoglobin decreased, haemoptysis, haemorrhage, haemorrhage coronary artery, haemorrhage urinary tract, haemorrhoidal haemorrhage, haemostasis, increased tendency to bruise, international normalized ratio increased, lower gastrointestinal haemorrhage, melaena, petechiae, pharyngeal haemorrhage, prothrombin time prolonged, pulmonary haemorrhage, purpura, rectal haemorrhage, red blood cell count decreased, renal haemorrhage, scleral haemorrhage, scrotal haematocoele, splenic haemotoma, splinter haemorrhage, subarachnoid haemorrhage, tongue haemorrhage, upper gastrointestinal haemorrhage and vaginal haemorrhage.</p><p><sup>i</sup>&nbsp;&nbsp; Including Budd-Chiari syndrome, deep vein thrombosis, jugular vein thrombosis, pelvic venous thrombosis, pulmonary embolism, retinal vein occlusion, retinal vein thrombosis, subclavian vein thrombosis, venous thrombosis, and venous thrombosis limb.</p><p><sup>j</sup>&nbsp; Including acute myocardial infarction, embolism, myocardial infarction, retinal artery occlusion and transient ischaemic attack.</p><p><sup>k</sup>&nbsp; Gastrointestinal perforation and fistula includes the following preferred terms: abdominal abscess, anal abscess, anal fistula, fistula, gastrointestinal anastomotic leak, gastrointestinal perforation, large intestine perforation, oesophagobronchial fistula and peritonitis.</p><p><sup>l</sup>&nbsp;&nbsp; Proteinuria includes the following preferred terms: protein urine, protein urine present and proteinuria.</p><p><sup>m</sup> Including acute renal failure</p><p><sup>n</sup> Cholecystitis includes Cholecystitis acute, Cholecystitis, Cholecystitis infective.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em><u>&nbsp;</u></em></p><p><em><u>Cardiac failure events<strong> </strong>(see section 4.4)</u></em></p><p>In a controlled clinical study with axitinib (N = 359) for the treatment of patients with RCC, cardiac failure events were reported in 1.7 % patients receiving axitinib, including cardiac failure (0.6%), cardiopulmonary failure (0.6%), left ventricular dysfunction (0.3%), and right ventricular failure (0.3%). Grade 4 cardiac failure adverse reactions were reported in 0.6 % of patients receiving axitinib. Fatal cardiac failure was reported in 0.6 % of patients receiving axitinib.</p><p>&nbsp;</p><p>In monotherapy studies with axitinib (N&nbsp;=&nbsp;672) for the treatment of patients with RCC, cardiac failure events (including cardiac failure, cardiac failure congestive, cardiopulmonary failure, left ventricular dysfunction, ejection fraction decreased, and right ventricular failure) were reported in 1.8% patients receiving axitinib. Grade 3/4 cardiac failure events were reported in 1.0% patients and fatal cardiac failure events were reported in 0.3% patients receiving axitinib<em>.<sup> </sup></em></p><p><em>&nbsp;</em></p><p><em><u>Thyroid dysfunction (see section&nbsp;4.4)</u></em></p><p>In a controlled clinical study with axitinib for the treatment of patients with RCC, hypothyroidism was reported in 20.9% of patients and hyperthyroidism was reported in 1.1% of patients. Thyroid stimulating hormone (TSH) increased was reported as an adverse reaction in 5.3% of patients receiving axitinib. During routine laboratory assessments, in patients who had TSH &lt;&nbsp;5&nbsp;&mu;U/mL before treatment, elevations of TSH to &ge;&nbsp;10&nbsp;&mu;U/mL occurred in 32.2% of patients receiving axitinib.</p><p>&nbsp;</p><p>In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, hypothyroidism was reported in 24.6% of patients receiving axitinib. Hyperthyroidism was reported in 1.6% of patients receiving axitinib.</p><p>&nbsp;</p><p><em><u>Venous embolic and thrombotic events (see section&nbsp;4.4)</u></em></p><p>In a controlled clinical study with axitinib for the treatment of patients with RCC, venous embolic and thrombotic adverse reactions were reported in 3.9% of patients receiving axitinib, including pulmonary embolism (2.2%), retinal vein occlusion/thrombosis (0.6%) and deep vein thrombosis&nbsp;(0.6%). Grade&nbsp;3/4 venous embolic and thrombotic adverse reactions were reported in 3.1% of patients receiving axitinib. Fatal pulmonary embolism was reported in one patient (0.3%) receiving axitinib.</p><p>&nbsp;</p><p>In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, venous embolic and thrombotic events were reported in 2.8% of patients receiving axitinib. Grade 3 venous embolic and thrombotic events were reported in 0.9% of patients. Grade 4 venous embolic and thrombotic events were reported in 1.2% of patients. Fatal venous embolic and thrombotic events were reported 0.1% patients receiving axitinib.</p><p>&nbsp;</p><p><em><u>Arterial embolic and thrombotic events (see section&nbsp;4.4)</u></em></p><p>In a controlled clinical study with axitinib for the treatment of patients with RCC, arterial embolic and thrombotic adverse reactions were reported in 4.7% of patients receiving axitinib, including myocardial infarction (1.4%), transient ischemic attack (0.8%) and cerebrovascular accident (0.6%). Grade&nbsp;3/4 arterial embolic and thrombotic adverse reactions were reported in 3.3% of patients receiving axitinib. A fatal acute myocardial infarction and cerebrovascular accident was reported in one patient each (0.3%). In monotherapy studies with axitinib (N&nbsp;=&nbsp;850), arterial embolic and thrombotic adverse reactions (including transient ischemic attack, myocardial infarction, and cerebrovascular accident) were reported in 5.3% of patients receiving axitinib.</p><p>&nbsp;</p><p>In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, arterial embolic and thrombotic events were reported in 2.8% of patients receiving axitinib. Grade 3 arterial embolic and thrombotic events were reported in 1.2% of patients. Grade 4 arterial embolic and thrombotic events were reported in 1.3% of patients. Fatal arterial embolic and thrombotic events were reported in 0.3% patients receiving axitinib.</p><p>&nbsp;</p><p><em><u>Polycythaemia (see Elevation of haemoglobin or haematocrit in section&nbsp;4.4)</u></em></p><p>In a controlled clinical study with axitinib for the treatment of patients with RCC, polycythaemia was reported in 1.4% of patients receiving axitinib. Routine laboratory assessments detected elevated haemoglobin above ULN in 9.7% of patients receiving axitinib. In four clinical studies with axitinib for the treatment of patients with RCC (N&nbsp;=&nbsp;537), elevated haemoglobin above ULN was observed in 13.6% receiving axitinib.</p><p>&nbsp;</p><p>In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, polycythaemia was reported in 1.5% of patients receiving axitinib.</p><p>&nbsp;</p><p><em><u>Haemorrhage (see section&nbsp;4.4)</u></em></p><p>In a controlled clinical study with axitinib for the treatment of patients with RCC that excluded patients with untreated brain metastasis, haemorrhagic adverse reactions were reported in 21.4% of patients receiving axitinib. The haemorrhagic adverse reactions in patients treated with axitinib included epistaxis (7.8%), haematuria (3.6%), haemoptysis (2.5%), rectal haemorrhage (2.2%), gingival bleeding (1.1%), gastric haemorrhage (0.6%), cerebral haemorrhage (0.3%) and lower gastrointestinal haemorrhage (0.3%). Grade&nbsp;<u>&gt;</u>&nbsp;3 haemorrhagic adverse reactions were reported in 3.1% of patients receiving axitinib (including cerebral haemorrhage, gastric haemorrhage, lower gastrointestinal haemorrhage and haemoptysis). Fatal haemorrhage was reported in one patient (0.3%) receiving axitinib (gastric haemorrhage). In monotherapy studies with axitinib (N&nbsp;=&nbsp;850), haemoptysis was reported in 3.9% of patients; Grade&nbsp;<u>&gt;</u>&nbsp;3 haemoptysis was reported in 0.5% of patients.</p><p>&nbsp;</p><p>In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, haemorrhagic events were reported in 25.7% of patients receiving axitinib. Grade 3 haemorrhagic adverse reactions were reported in 3% of patients. Grade 4 haemorrhagic adverse reactions were reported in 1% of patients and fatal haemorrhage were reported in 0.4% of patients receiving axitinib.</p><p>&nbsp;</p><p><em><u>Gastrointestinal perforation and fistula formation (see section&nbsp;4.4)</u></em></p><p>In a controlled clinical study with axitinib for the treatment of patients with RCC, gastrointestinal perforation-type events were reported in 1.7% of patients receiving axitinib, including anal fistula&nbsp;(0.6%), fistula (0.3%) and gastrointestinal perforation (0.3%).In monotherapy studies with axitinib (N&nbsp;=&nbsp;850), gastrointestinal perforation-type events were reported in 1.9% of patients and fatal gastrointestinal perforation was reported in one patient (0.1%).</p><p>&nbsp;</p><p>In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, gastrointestinal perforation and fistula were reported in 1.9% of patients receiving axitinib.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for axitinib overdose.</p><p>&nbsp;</p><p>In a controlled clinical study with axitinib for the treatment of patients with RCC, one patient inadvertently received a dose of 20&nbsp;mg twice daily for 4 days and experienced dizziness (Grade&nbsp;1).</p><p>&nbsp;</p><p>In a clinical dose finding study with axitinib, subjects who received starting doses of 10&nbsp;mg twice daily or 20&nbsp;mg twice daily experienced adverse reactions which included hypertension, seizures associated with hypertension, and fatal haemoptysis.</p><p>&nbsp;</p><p>In cases of suspected overdose, axitinib should be withheld and supportive care instituted.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:<strong><em> </em></strong>Antineoplastic agents, protein kinase inhibitors, ATC code: L01EK01</p><p><em>&nbsp;</em></p><p><u>Mechanism of action</u></p><p>Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2 and VEGFR-3. These receptors are implicated in pathologic angiogenesis, tumour growth, and metastatic progression of cancer. Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival. Axitinib inhibited the phosphorylation of VEGFR-2 in xenograft tumour vasculature that expressed the target <em>in vivo</em> and produced tumour growth delay, regression, and inhibition of metastases in many experimental models of cancer.</p><p><em>&nbsp;</em></p><p><u>Effect on QTc interval</u></p><p>In a randomised, 2-way crossover study, 35&nbsp;healthy subjects were administered a single oral dose of axitinib&nbsp;(5&nbsp;mg) in the absence and presence of 400&nbsp;mg ketoconazole for 7&nbsp;days. Results of this study indicated that axitinib plasma exposures up to two‑fold greater than therapeutic levels expected following a 5&nbsp;mg dose, did not produce clinically-significant QT interval prolongation.</p><p><em>&nbsp;</em></p><p><u>Clinical efficacy and safety</u></p><p>The safety and efficacy of axitinib were evaluated in a randomised, open-label, multicenter Phase&nbsp;3 study. Patients (N&nbsp;=&nbsp;723) with advanced RCC whose disease had progressed on or after treatment with one prior systemic therapy, including sunitinib-, bevacizumab-, temsirolimus-, or cytokine-containing regimens were randomised (1:1) to receive axitinib (N&nbsp;=&nbsp;361) or sorafenib (N&nbsp;=&nbsp;362). The primary endpoint, progression-free survival (PFS), was assessed using a blinded independent central review. Secondary endpoints included objective response rate (ORR) and overall survival (OS).</p><p>&nbsp;</p><p>Of the patients enrolled in this study, 389&nbsp;patients (53.8%) had received one prior sunitinib-based therapy, 251&nbsp;patients (34.7%) had received one prior cytokine-based therapy (interleukin-2 or interferon-alpha), 59&nbsp;patients (8.2%) had received one prior bevacizumab-based therapy, and 24&nbsp;patients (3.3%) had received one prior temsirolimus-based therapy. The baseline demographic and disease characteristics were similar between the axitinib and sorafenib groups with regard to age, gender, race, Eastern Cooperative Oncology Group (ECOG) performance status, geographic region, and prior treatment.</p><p>&nbsp;</p><p>In the overall patient population and the two main subgroups (prior sunitinib treatment and prior cytokine treatment), there was a statistically significant advantage for axitinib over sorafenib for the primary endpoint of PFS (see Table&nbsp;2 and Figures&nbsp;1, 2 and 3). The magnitude of median PFS effect was different in the subgroups by prior therapy. Two of the subgroups were too small to give reliable results (prior temsirolimus treatment or prior bevacizumab treatment). There were no statistically significant differences between the arms in OS in the overall population or in the subgroups by prior therapy.</p><p>&nbsp;</p><p><strong>Table 2. Efficacy results</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td><p><strong>Endpoint / study population</strong></p></td><td><p><strong>axitinib </strong></p></td><td><p><strong>sorafenib</strong></p></td><td><p><strong>HR</strong> <strong>(95% CI)</strong></p></td><td><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Overall ITT</strong></p></td><td style="vertical-align:top"><p><strong>N = 361</strong></p></td><td style="vertical-align:top"><p><strong>N = 362</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>Median PFS<sup> a,b</sup> in months<br />(95% CI)</p></td><td style="vertical-align:top"><p>6.8 (6.4, 8.3)</p></td><td style="vertical-align:top"><p>4.7 (4.6, 6.3)</p></td><td style="vertical-align:top"><p>0.67 (0.56, 0.81)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001<sup>c</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>Median OS <sup>d</sup> in months<br />(95% CI)</p></td><td style="vertical-align:top"><p>20.1 (16.7, 23.4)</p></td><td style="vertical-align:top"><p>19.2 (17.5, 22.3)</p></td><td style="vertical-align:top"><p>0.97 (0.80, 1.17)</p></td><td style="vertical-align:top"><p>NS</p></td></tr><tr><td style="vertical-align:bottom"><p>ORR<sup> b,e</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>19.4 (15.4, 23.9)</p></td><td style="vertical-align:top"><p>9.4 (6.6, 12.9)</p></td><td style="vertical-align:top"><p>2.06<sup>f</sup> (1.41, 3.00)</p></td><td style="vertical-align:top"><p>0.0001<sup>g</sup></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Prior sunitinib treatment</strong></p></td><td style="vertical-align:top"><p><strong>N = 194</strong></p></td><td style="vertical-align:top"><p><strong>N = 195</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>Median PFS<sup> a,b</sup> in months<br />(95% CI)</p></td><td style="vertical-align:top"><p>4.8 (4.5, 6.5)</p></td><td style="vertical-align:top"><p>3.4 (2.8, 4.7)</p></td><td style="vertical-align:top"><p>0.74 (0.58, 0.94)</p></td><td style="vertical-align:top"><p>0.0063<sup>h</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>Median OS<sup> d</sup> in months<br />(95% CI)</p></td><td style="vertical-align:top"><p>15.2 (12.8, 18.3)</p></td><td style="vertical-align:top"><p>16.5 (13.7, 19.2)</p></td><td style="vertical-align:top"><p>1.00 (0.78, 1.27)</p></td><td style="vertical-align:top"><p>NS</p></td></tr><tr><td style="vertical-align:bottom"><p>ORR<sup> b,e</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>11.3 (7.2, 16.7)</p></td><td style="vertical-align:top"><p>7.7 (4.4, 12.4)</p></td><td style="vertical-align:top"><p>1.48<sup>f</sup> (0.79, 2.75)</p></td><td style="vertical-align:top"><p>NS</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Prior cytokine treatment</strong></p></td><td style="vertical-align:top"><p><strong>N = 126</strong></p></td><td style="vertical-align:top"><p><strong>N = 125</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>Median PFS<sup> a,b</sup> in months<br />(95% CI)</p></td><td style="vertical-align:top"><p>12.0 (10.1, 13.9)</p></td><td style="vertical-align:top"><p>6.6 (6.4, 8.3)</p></td><td style="vertical-align:top"><p>0.52 (0.38, 0.72)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001<sup>h</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>Median OS<sup> d</sup> in months<br />(95% CI)</p></td><td style="vertical-align:top"><p>29.4 (24.5, NE)</p></td><td style="vertical-align:top"><p>27.8 (23.1, 34.5)</p></td><td style="vertical-align:top"><p>0.81 (0.56, 1.19)</p></td><td style="vertical-align:top"><p>NS</p></td></tr><tr><td style="vertical-align:bottom"><p>ORR<sup> b,e</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>32.5 (24.5, 41.5)</p></td><td style="vertical-align:top"><p>13.6 (8.1, 20.9)</p></td><td style="vertical-align:top"><p>2.39<sup>f</sup> (1.43-3.99)</p></td><td style="vertical-align:top"><p>0.0002<sup>i</sup></p></td></tr></tbody></table><p>CI&nbsp;=&nbsp;Confidence interval, HR&nbsp;=&nbsp;Hazard ratio (axitinib/sorafenib); ITT: Intent-to-treat; NE: not estimable; NS: not statistically significant; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival.</p><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Time from randomisation to progression or death due to any cause, whichever occurs first. Cutoff date:&nbsp;03&nbsp;June 2011.</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Assessed by independent radiology review according to Response Evaluation Criteria in Solid Tumours (RECIST).</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp; One-sided p-value from a log-rank test of treatment stratified by ECOG performance status and prior therapy.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp; Cutoff date: 01 November 2011.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp; Cutoff date: 31 August 2010.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp; Risk ratio is used for ORR. A risk ratio &gt;&nbsp;1 indicated a higher likelihood of responding in the axitinib arm; a risk ratio &lt;&nbsp;1 indicated a higher likelihood of responding in the sorafenib arm.</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp; One-sided p-value from Cochran-Mantel-Haenszel test of treatment stratified by ECOG performance status and prior therapy.</p><p><sup>h&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>One-sided p-value from a log-rank test of treatment stratified by ECOG performance status.</p><p><sup>i</sup>&nbsp;&nbsp;&nbsp;&nbsp; One-sided p-value from Cochran-Mantel-Haenszel test of treatment stratified by ECOG performance status.</p><p>&nbsp;</p><p><strong>Figure 1. Kaplan-Meier curve of progression-free survival by independent assessment for the overall population</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1027" type="#_x0000_t75" alt="New_ax.tif"
 style='width:412.5pt;height:230pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title="New_ax" croptop="10922f" cropbottom="13107f" cropleft="3277f"
  cropright="6554f"/>
</v:shape><![endif]--><img width="550" height="307" alt="New_ax.tif" src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /></p><p>&nbsp;</p><p><strong>Figure 2. Kaplan-Meier curve of progression-free survival by independent assessment for the prior sunitinib subgroup</strong></p><p><strong><!--[if gte vml 1]><v:shape
 id="Picture_x0020_2" o:spid="_x0000_i1026" type="#_x0000_t75" alt="SmPC_sutent-refractory KM"
 style='width:418.5pt;height:246pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
  o:title="SmPC_sutent-refractory KM" croptop="11549f" cropbottom="12940f"
  cropleft="3177f" cropright="3177f"/>
</v:shape><![endif]--><img width="558" height="328" alt="SmPC_sutent-refractory KM" src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.gif" /></strong></p><p><strong>Figure 3. Kaplan-Meier curve of progression-free survival by independent assessment for the prior cytokine subgroup</strong></p><p><em><!--[if gte vml 1]><v:shape id="Picture_x0020_3" o:spid="_x0000_i1025"
 type="#_x0000_t75" alt="SmPC_cytokine refractory KM" style='width:412pt;
 height:238.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png"
  o:title="SmPC_cytokine refractory KM" croptop="13020f" cropbottom="12731f"
  cropleft="3798f" cropright="4123f"/>
</v:shape><![endif]--><img width="549" height="318" alt="SmPC_cytokine refractory KM" src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.gif" /></em></p><p><strong><em>&nbsp;</em></strong></p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with axitinib in all subsets of the paediatric population for treatment of kidney and renal pelvis carcinoma (excluding nephroblastoma, nephroblastomatosis, clear cell sarcoma, mesoblastic nephroma, renal medullary carcinoma and rhabdoid tumour of the kidney) (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After oral administration of axitinib tablets, the mean absolute bioavailability is 58% compared to intravenous administration. The plasma half life of axitinib ranges from 2.5&nbsp;to 6.1&nbsp;hours. Dosing of axitinib at 5&nbsp;mg twice daily resulted in less than two‑fold accumulation compared to administration of a single dose. Based on the short half-life of axitinib, steady state is expected within 2&nbsp;to 3&nbsp;days of the initial dose.</p><p>&nbsp;</p><p><u>Absorption and distribution</u></p><p>Peak axitinib concentrations in plasma are generally reached within 4 hours following oral administration of axitinib with median T<sub>max</sub> ranging from 2.5&nbsp;to 4.1&nbsp;hours. Administration of axitinib with a moderate fat meal resulted in 10% lower exposure compared to overnight fasting. A high fat, high-calorie meal resulted in 19% higher exposure compared to overnight fasting. Axitinib may be administered with or without food (see section&nbsp;4.2).</p><p>&nbsp;</p><p>The average C<sub>max</sub> and AUC increased proportionally over an axitinib dosing range of 5&nbsp;to 10&nbsp;mg. <em>In&nbsp;vitro</em> binding of axitinib to human plasma proteins is &gt;&nbsp;99% with preferential binding to albumin and moderate binding to &alpha;<sub>1</sub>-acid glycoprotein. At the 5&nbsp;mg twice daily dose in the fed state, the geometric mean peak plasma concentration and 24‑hour AUC were 27.8&nbsp;ng/mL and 265&nbsp;ng.h/mL, respectively, in patients with advanced RCC. The geometric mean oral clearance and apparent volume of distribution were 38&nbsp;L/h and 160&nbsp;L, respectively.</p><p><em>&nbsp;</em></p><p><u>Biotransformation and elimination</u></p><p>Axitinib is metabolised primarily in the liver by CYP3A4/5 and to a lesser extent by CYP1A2, CYP2C19, and UGT1A1.</p><p>&nbsp;</p><p>Following oral administration of a 5&nbsp;mg radioactive dose of axitinib, 30-60% of the radioactivity was recovered in faeces and 23% of the radioactivity was recovered in urine. Unchanged axitinib, accounting for 12% of the dose, was the major component identified in faeces. Unchanged axitinib was not detected in urine; the carboxylic acid and sulfoxide metabolites accounted for the majority of radioactivity in urine. In plasma, the N-glucuronide metabolite represented the predominant radioactive component (50% of circulating radioactivity) and unchanged axitinib and the sulfoxide metabolite each accounted for approximately 20% of the circulating radioactivity.</p><p>&nbsp;</p><p>The sulfoxide and N-glucuronide metabolites show approximately 400‑fold and 8000‑fold less <em>in vitro </em>potency, respectively, against VEGFR‑2 compared to axitinib.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><em><u>Elderly, gender, and race</u></em></p><p>Population pharmacokinetic analyses in patients with advanced cancer (including advanced RCC) and healthy volunteers indicate that there are no clinically relevant effects of age, gender, body weight, race, renal function, UGT1A1 genotype, or CYP2C19 genotype.</p><p><em>&nbsp;</em></p><p><em><u>Paediatric population</u></em></p><p>Axitinib has not been studied in patients &lt;&nbsp;18 years of age.</p><p><em>&nbsp;</em></p><p><em><u>Hepatic impairment</u></em></p><p><em>In vitro</em> and <em>in vivo</em> data indicate that axitinib is primarily metabolised by the liver.</p><p>&nbsp;</p><p>Compared to subjects with normal hepatic function, systemic exposure following a single dose of axitinib was similar in subjects with mild hepatic impairment (Child-Pugh class&nbsp;A) and higher (approximately two‑fold) in subjects with moderate hepatic impairment (Child-Pugh class&nbsp;B). Axitinib has not been studied in subjects with severe hepatic impairment (Child-Pugh class&nbsp;C) and should not be used in this population (see section&nbsp;4.2 for dose adjustment recommendations).</p><p><em>&nbsp;</em></p><p><em><u>Renal impairment</u></em></p><p>Unchanged axitinib is not detected in the urine.</p><p>&nbsp;</p><p>Axitinib has not been studied in subjects with renal impairment. In clinical studies with axitinib for the treatment of patients with RCC, patients with serum creatinine &gt;&nbsp;1.5&nbsp;times the ULN or calculated creatinine clearance &lt;&nbsp;60&nbsp;mL/min were excluded. Population pharmacokinetic analyses have shown that axitinib clearance was not altered in subjects with renal impairment and no dose adjustment of axitinib is required.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Repeat dose toxicity</u></p><p>Major toxicity findings in mice and dogs following repeated dosing for up to 9&nbsp;months were the gastrointestinal, haematopoietic, reproductive, skeletal and dental systems, with No Observed Adverse Effect Levels (NOAEL) approximately equivalent to or below expected human exposure at the recommended clinical starting dose (based on AUC levels).</p><p><em>&nbsp;</em></p><p><u>Carcinogenicity</u></p><p>Carcinogenicity studies have not been performed with axitinib.</p><p>&nbsp;</p><p><u>Genotoxicity</u></p><p>Axitinib was not mutagenic or clastogenic in conventional genotoxicity assays <em>in vitro</em>. A significant increase in polyploidy was observed <em>in vitro</em> at concentrations &gt;&nbsp;0.22&nbsp;&micro;g/mL, and an elevation in micronucleated polychromatic erythrocytes was observed <em>in vivo</em> with No Observed Effect Level (NOEL) 69‑fold the expected human exposure. Genotoxicity findings are not considered clinically relevant at exposure levels observed in humans.</p><p><em>&nbsp;</em></p><p><u>Reproduction toxicity</u></p><p>Axitinib-related findings in the testes and epididymis included decreased organ weight, atrophy or degeneration, decreased numbers of germinal cells, hypospermia or abnormal sperm forms, and reduced sperm density and count. These findings were observed in mice at exposure levels approximately 12‑fold the expected human exposure, and in dogs at exposure levels below the expected human exposure. There was no effect on mating or fertility in male mice at exposure levels approximately 57‑fold the expected human exposure. Findings in females included signs of delayed sexual maturity, reduced or absent corpora lutea, decreased uterine weights and uterine atrophy at exposures approximately equivalent to the expected human exposure. Reduced fertility and embryonic viability were observed in female mice at all doses tested, with exposure levels at the lowest dose approximately 10‑fold the expected human exposure.</p><p>&nbsp;</p><p>Pregnant mice exposed to axitinib showed an increased occurrence of cleft palate malformations and skeletal variations, including delayed ossification, at exposure levels below the expected human exposure. Perinatal and postnatal developmental toxicity studies have not been conducted.<em> </em></p><p>&nbsp;</p><p><u>Toxicity findings in immature animals</u></p><p>Reversible physeal dysplasia was observed in mice and dogs given axitinib for at least 1 month at exposure levels approximately six‑fold higher than the expected human exposure. Partially reversible dental caries were observed in mice treated for more than 1 month at exposure levels similar to the expected human exposure. Other toxicities of potential concern to paediatric patients have not been evaluated in juvenile animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Microcrystalline cellulose</p><p>Lactose monohydrate</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Tablet film-coating</u></p><p>Hypromellose 2910 (15 mPa&middot;s)</p><p>Titanium dioxide (E171)</p><p>Lactose monohydrate</p><p>Triacetin (E1518)</p><p>Iron oxide red (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
Do not use Inlyta after the expiry date which is stated on the carton after EXP:. The expiry date refers to the last day of that month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Inlyta 1 mg film-coated tablet</u></p><p>Aluminium/aluminium blister containing 14 film-coated tablets. Each pack contains 56&nbsp;film‑coated tablets.</p><p>&nbsp;</p><p>For the pack of 56 tablets, the pack contains 4 blisters each blister has 14 film coated tablets (4 X 14).</p><p><u>&nbsp;</u></p><p><u>Inlyta 5 mg film-coated tablet</u></p><p>Aluminium/aluminium blister containing 14 film-coated tablets. Each pack contains 56&nbsp;film‑coated tablets.</p><p>&nbsp;</p><p>For the pack of 56 tablets, the pack contains 4 blisters each blister has 14 film coated tablets (4 X 14).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
Pfizer Europe MA EEIG
Belgium

	Manufacturer
Pfizer Manufacturing Deutschland GmbH
Betriebsstätte Freiburg
Mooswaldallee 1
79090 Freiburg
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>